ADS024, a Bacillus velezensis strain, protects human colonic epithelial cells against C. difficile toxin-mediated apoptosis

por Xie, Ying, Chupina Estrada, Andrea, Nelson, Becca, Feng, Hanping, Pothoulakis, Charalabos, Chesnel, Laurent, Koon, Hon Wai
Publicado 2023

The Capping Domain in RalF Regulates Effector Functions

por Alix, Eric, Chesnel, Laurent, Bowzard, Brad J., Tucker, Aimee M., Delprato, Anna, Cherfils, Jacqueline, Wood, David O., Kahn, Richard A., Roy, Craig R.
Publicado 2012

Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo

por Murphy, Christopher K, O’Donnell, Michelle M, Hegarty, James W, Schulz, Sarah, Hill, Colin, Ross, R Paul, Rea, Mary C, Farquhar, Ronald, Chesnel, Laurent
Publicado 2023

Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection

por Boix, Vicente, Fedorak, Richard N., Mullane, Kathleen M., Pesant, Yves, Stoutenburgh, Uschi, Jin, Mandy, Adedoyin, Adedayo, Chesnel, Laurent, Guris, Dalya, Larson, Kajal B., Murata, Yoshihiko
Publicado 2017

Identification of ADS024, a newly characterized strain of Bacillus velezensis with direct Clostridiodes difficile killing and toxin degradation bio-activities

por O’Donnell, Michelle M., Hegarty, James W., Healy, Brian, Schulz, Sarah, Walsh, Calum J., Hill, Colin, Ross, R. Paul, Rea, Mary C., Farquhar, Ronald, Chesnel, Laurent
Publicado 2022